SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

Immunexpress.com

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Read More

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

Immunexpress.com

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…

Read More

American Thoracic Society (ATS) 2016 International Conference

American Thoracic Society 2016 May 13-18, 2016 San Francisco, CA. Bert Lopansri of Intermountain Health Care presented data on the usage of SeptiCyte™ technology to better inform management and reduce risk for patients in the early stages of ICU admission when other diagnostics available at this time either lack accuracy or are not available.

Read More